Home / Health / Drug Pioneer John Lewis's Legacy: Saving Millions
Drug Pioneer John Lewis's Legacy: Saving Millions
24 Nov
Summary
- Lewis developed buprenorphine as an alternative painkiller and addiction treatment.
- His work at Reckitt & Colman led to treatments used by millions globally.
- He received international recognition, including congratulations from royalty and a US president.
John Lewis, who passed away at 92, was a pivotal figure in pharmaceutical research, renowned for his lead role in developing buprenorphine. This drug has since become a successful alternative to morphine for pain management and a critical treatment for opioid addiction, impacting millions globally.
Lewis's groundbreaking work primarily occurred during his tenure as research and development director at Reckitt & Colman pharmaceuticals and later at Bristol University. His dedication to psychopharmacology research continued independently, culminating in his retirement in 2018. His contributions were acknowledged with prestigious awards and letters of congratulations from Queen Elizabeth II and President Bill Clinton.
The development of buprenorphine, alongside pharmacologist Alan Cowan, is considered Lewis's greatest scientific achievement. This innovation provided a vital treatment option for opioid dependence, particularly heroin addiction, and has become a leading medication for opioid substitution therapy worldwide.
